Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06782659 · ClinicalTrials.gov registry record · Phase 1
Study to Compare the Effects of Viagra® Vs Hezkue® in Healthy Fasted Male Participants.
A Phase 1 study, sponsored by Aspargo Labs.
- Not yet
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT06782659 is a Phase 1 study that has not yet begun recruiting, run by Aspargo Labs. The registered enrollment target is 56 participants.
The verdict
NCT06782659, a Phase 1 study, has not yet begun recruiting, sponsored by Aspargo Labs.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The objective of this phase 1, open-label, single-center, two-way crossover trial is to evaluate the pharmacokinetics (PK), safety, and tolerability of 100 mg ASP-001 oral liquid suspension versus 100 mg Viagra (sildenafil citrate) tablets in fasted, healthy male volunteers
Interventions
- DRUG ASP-001
- DRUG Viagra
- DEVICE ASP-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-01 |
| Est. Completion | 2025-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06782659
The ClinicalTrials.gov registry entry for NCT06782659 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aspargo Labs, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ASP-001 is the first listed.
NCT06782659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06782659 about?
NCT06782659 is a clinical study titled "Study to Compare the Effects of Viagra® Vs Hezkue® in Healthy Fasted Male Participants.". The objective of this phase 1, open-label, single-center, two-way crossover trial is to evaluate the pharmacokinetics (PK), safety, and tolerability of 100 mg ASP-001 oral liquid suspension versus 100 mg Viagra (sildenafil citrate) tablets in fasted, healthy male volunteers
What is the current status of trial NCT06782659?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2025-01. Estimated completion is 2025-03.
What interventions are being tested in trial NCT06782659?
The interventions under investigation include: ASP-001 (DRUG), Viagra (DRUG), ASP-001 (DEVICE).
Who is sponsoring clinical trial NCT06782659?
This trial is sponsored by Aspargo Labs, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.